Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients
Top Cited Papers
- 29 September 2010
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (19), 7392-7399
- https://doi.org/10.1158/0008-5472.can-10-2027
Abstract
Resveratrol is a phytochemical with chemopreventive activity in preclinical rodent models of colorectal carcinogenesis. Antiproliferation is one of the many chemopreventive modes of action it has been shown to engage in. Concentrations of resveratrol, which can be achieved in human tissues after p.o. administration, have not yet been defined. The purpose of this study was to measure concentrations of resveratrol and its metabolites in the colorectal tissue of humans who ingested resveratrol. Twenty patients with histologically confirmed colorectal cancer consumed eight daily doses of resveratrol at 0.5 or 1.0 g before surgical resection. Resveratrol was found to be well tolerated. Normal and malignant biopsy tissue samples were obtained before dosing. Parent compound plus its metabolites resveratrol-3-O-glucuronide, resveratrol-4′-O-glucuronide, resveratrol-3-O-sulfate, resveratrol-4′-O-sulfate, resveratrol sulfate glucuronide, and resveratrol disulfate were identified by high-performance liquid chromatography (HPLC) with UV or mass spectrometric detection in colorectal resection tissue. Quantitation was achieved by HPLC/UV. Cell proliferation, as reflected by Ki-67 staining, was compared in preintervention and postintervention tissue samples. Resveratrol and resveratrol-3-O-glucuronide were recovered from tissues at maximal mean concentrations of 674 and 86.0 nmol/g, respectively. Levels of resveratrol and its metabolites were consistently higher in tissues originating in the right side of the colon compared with the left. Consumption of resveratrol reduced tumor cell proliferation by 5% (P = 0.05). The results suggest that daily p.o. doses of resveratrol at 0.5 or 1.0 g produce levels in the human gastrointestinal tract of an order of magnitude sufficient to elicit anticarcinogenic effects. Resveratrol merits further clinical evaluation as a potential colorectal cancer chemopreventive agent. Cancer Res; 70(19); 7392–9. ©2010 AACR.Keywords
This publication has 27 references indexed in Scilit:
- Resveratrol Suppresses Colitis and Colon Cancer Associated with ColitisCancer Prevention Research, 2010
- Pharmacokinetic and safety profile of trans‐resveratrol in a rising multiple‐dose study in healthy volunteersMolecular Nutrition & Food Research, 2009
- Mitocans, a class of emerging anti‐cancer drugsMolecular Nutrition & Food Research, 2009
- Resveratrol: A review of preclinical studies for human cancer preventionToxicology and Applied Pharmacology, 2007
- Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive AgentCancer Epidemiology, Biomarkers & Prevention, 2007
- Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatographyJournal of Chromatography B, 2007
- Diagnostic Performance of Urinary Resveratrol Metabolites as a Biomarker of Moderate Wine ConsumptionClinical Chemistry, 2006
- Therapeutic potential of resveratrol: the in vivo evidenceNature Reviews Drug Discovery, 2006
- Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4′‐tetramethoxystilbene (DMU‐212) on adenoma development in the ApcMin+ mouse and cyclooxygenase‐2 in human‐derived colon cancer cellsInternational Journal of Cancer, 2005
- Urinary and Plasma Levels of Resveratrol and Quercetin in Humans, Mice, and Rats after Ingestion of Pure Compounds and Grape JuiceJournal of Agricultural and Food Chemistry, 2004